Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|January 30, 2014
The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC
Author(s)Rana R. McKay, MD
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.
Advertisement
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who used angiotensin system inhibitors (ASI).Read more about this trial > >
- This study evaluated OS in ASI users versus nonusers in patients with mRCC
- OS was 27 months compared to 17 months (ASI users vs nonusers, respectively; hazard ratio=1.2)
- In a subset analysis stratified by types of therapy for mRCC (including VEGF-targeted therapy, mTOR-targeted therapy, and IFN-α therapy), the only statistically significant OS benefit was seen in patients receiving VEGF-targeted therapy
<<<
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5